ArrowMark Colorado Holdings’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-453,643	Closed	-$31.7M	–	331
2022 Q3	$31.7M	Buy	+453,643	New	+$33.6M	0.39%	76
2016 Q4	–	Sell	-2,482	Closed	-$16K	–	465
2016 Q3	$16K	Buy	+2,482	New	+$13.2K	﹤0.01%	325
2016 Q1	–	Sell	-17,122	Closed	-$541K	–	278
2015 Q4	$541K	Hold	17,122	–	–	0.01%	247
2015 Q3	$589K	Buy	+17,122	New	+$518K	0.02%	247

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ArrowMark Colorado Holdings's MRTX Position: Q4 2022 in Review

ArrowMark Colorado Holdings sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 453,643 shares — an estimated $31.7M sold.

ArrowMark Colorado Holdings first reported a position in MRTX in Q3 2015 and held it in 4 quarters. The position peaked at $31.7M in Q3 2022. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

ArrowMark Colorado Holdings reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
ArrowMark Colorado Holdings sold 453,643 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $31.7M.
ArrowMark Colorado Holdings first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 4 quarters.
ArrowMark Colorado Holdings's Mirati Therapeutics, Inc. Common Stock position peaked at $31.7M in Q3 2022.
233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.